An unbiased screen of 673 genetically characterized tumor-derived cell lines shows that neuroblastoma cell lines with MYCN amplification are more sensitive to JQ1 treatment compared to MYCN-wild-type tumors. This evidence concerns the gene MYCN and neoplasm.